Progress on research and development of drug for chronic kidney disease and related comorbidities
10.16438/j.0513-4870.2022-0134
- VernacularTitle:慢性肾病及相关并发症治疗药物研究进展
- Author:
Yi-ge YANG
1
,
2
;
He LI
1
;
Xiu-li ZHANG
1
;
Xiao-chuan TAN
1
;
Yu-jia ZHANG
1
;
Wen-sheng ZHENG
1
Author Information
1. Beijing City Key Laboratory of Drug Delivery Technology and Novel Formulation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
2. Tianjin University, Tianjin 100072, China
- Publication Type:Research Article
- Keywords:
chronic kidney disease;
comorbidity;
rug development;
end-stage renal disease;
clinical trial drug
- From:
Acta Pharmaceutica Sinica
2022;57(9):2682-2695
- CountryChina
- Language:Chinese
-
Abstract:
Chronic kidney disease (CKD) is a progressive disease with many complications (eg, cardiovascular disease and acidosis and anemia) and high morbidity and mortality occurs in the population. There is no cure for this disease, current treatments including renin-angiotensin-aldosterone pathway inhibitors and sodium-glucose co-transporter 2 inhibitors can only delay the progression to end-stage renal disease. With the identification of more key factors and mechanisms in CKD development, new potential therapeutic approaches for CKD can be developed. This review summarizes the mainstays of therapy and strategies for CKD and related comorbidities to support the development of novel treatments.
